15,682 Shares of Illumina, Inc. $ILMN Bought by Private Advisory Group LLC

Private Advisory Group LLC acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 15,682 shares of the life sciences company’s stock, valued at approximately $4,292,000.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. acquired a new position in Illumina during the second quarter worth approximately $3,374,423,000. Plato Investment Management Ltd purchased a new position in Illumina during the second quarter worth approximately $948,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Illumina in the 2nd quarter valued at $30,501,000. Edmond DE Rothschild Holding S.A. acquired a new position in shares of Illumina in the 2nd quarter valued at $129,792,000. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new position in shares of Illumina in the 2nd quarter valued at $6,711,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Key Illumina News

Here’s some of the latest news about ILMN:

• Positive Sentiment: Illumina reported third-quarter revenue of $1.129 billion and net income of $220 million, raised its 2026 revenue outlook to $4.64 billion–$4.66 billion, and highlighted strength in clinical sequencing consumables. How Investors May Respond To Illumina (ILMN) Earnings Beat
• Positive Sentiment: The company expanded its molecular residual disease research portfolio with an ultrasensitive duplex sequencing workflow for circulating tumor DNA and was selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT precision-medicine study. These developments support its push into clinical oncology and sequencing applications. Illumina (ILMN) Unveils Duplex Sequencing Workflow For MRD Research
• Negative Sentiment: Director Keith Meister sold 280,091 shares over November 9–11 for approximately $61.1 million, reducing his direct holdings to 208,826 shares. The scale of the sales could raise concerns among investors, despite his continuing substantial ownership. SEC filing

Illumina Stock Down 1.6%

Shares of Illumina stock opened at $209.55 on Friday. Illumina, Inc. has a twelve month low of $112.65 and a twelve month high of $309.35. The stock has a market cap of $31.68 billion, a price-to-earnings ratio of 36.07, a price-to-earnings-growth ratio of 2.89 and a beta of 1.46. The company has a current ratio of 2.63, a quick ratio of 2.05 and a debt-to-equity ratio of 0.57. The company has a fifty day moving average price of $249.32 and a 200 day moving average price of $179.36.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.36 by $0.26. The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The company’s revenue was up 4.2% on a year-over-year basis. During the same period last year, the business posted $1.34 EPS. Equities research analysts forecast that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Illumina news, Director Keith Meister sold 98,833 shares of the firm’s stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $216.87, for a total transaction of $21,433,912.71. Following the completion of the transaction, the director directly owned 208,826 shares of the company’s stock, valued at $45,288,094.62. This trade represents a 32.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Scott Ericksen sold 267 shares of the business’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $217.76, for a total value of $58,141.92. Following the completion of the sale, the chief accounting officer directly owned 14,029 shares of the company’s stock, valued at approximately $3,054,955.04. This represents a 1.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,881,899 shares of company stock valued at $415,905,954 in the last three months. Corporate insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ILMN shares. Wall Street Zen cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. Stephens lowered Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 target price on the stock. in a research report on Friday, October 23rd. Leerink Partners lifted their target price on Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. Citigroup lifted their target price on Illumina from $113.00 to $210.00 and gave the company a “sell” rating in a report on Monday, November 2nd. Finally, Royal Bank Of Canada boosted their price target on Illumina from $230.00 to $310.00 and gave the company an “outperform” rating in a research report on Monday, October 5th. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, Illumina presently has an average rating of “Hold” and a consensus price target of $244.24.

Illumina Company Profile

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.